Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Market Leadership and Brand Recognition: Exact Sciences Corp has established itself as a market leader in the cancer screening industry, particularly with its flagship product, Cologuard.

An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback. Per the findings of the pivotal BLUE-C study, the Cologuard ...

Wells Fargo analyst Brandon Couillard assigned a Buy rating to Exact Sciences (EXAS – Research Report) yesterday and set a price target ...

Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in ...

Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Market Leadership and Brand Recognition: Exact Sciences Corp has established itself as a market leader in the cancer screening industry, particularly with its flagship product, Cologuard. The ...